← Eichor
Study identifier: NCT07219589 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants

Condition: Obesity · Obese  ·  Sponsor: Hanmi Pharmaceutical Company Limited

PhasePhase 1
Planned participants90
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersYes

About this study

This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HM17321 after single and multiple ascending doses in healthy and obese participants.

This description comes directly from the study's public registry record.

Talk to the study team

Jimin Han  ·  +82-2-410-9838  ·  jimin.han@hanmi.co.kr

Always discuss trial participation with your own doctor first.

Locations (1)

Medpace Clinical Pharmacology UnitCincinnati, Ohio, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07219589